| Membrane transporters in drug development Nature reviews Drug discovery 9 (3), 215-236, 2010 | 3488 | 2010 |
| Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection … P Mulvenna, M Nankivell, R Barton, C Faivre-Finn, P Wilson, E McColl, ... The Lancet 388 (10055), 2004-2014, 2016 | 681 | 2016 |
| Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4 KE Thummel, CA Lee, KL Kunze, SD Nelson, JT Slattery Biochemical pharmacology 45 (8), 1563-1569, 1993 | 368 | 1993 |
| Drug–Drug Interactions Mediated Through P‐Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug KS Fenner, MD Troutman, S Kempshall, JA Cook, JA Ware, DA Smith, ... Clinical pharmacology & therapeutics 85 (2), 173-181, 2009 | 306 | 2009 |
| Development of a new permeability assay using low‐efflux MDCKII cells L Di, C Whitney‐Pickett, JP Umland, H Zhang, X Zhang, DF Gebhard, ... Journal of pharmaceutical sciences 100 (11), 4974-4985, 2011 | 277 | 2011 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 218 | 2022 |
| ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport‐mediated PK and DDIs in humans MJ Zamek‐Gliszczynski, CA Lee, A Poirier, J Bentz, X Chu, H Ellens, ... Clinical Pharmacology & Therapeutics 94 (1), 64-79, 2013 | 216 | 2013 |
| Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment … J Bentz, MP O’Connor, D Bednarczyk, JA Coleman, C Lee, J Palm, ... Drug metabolism and disposition 41 (7), 1347-1366, 2013 | 169 | 2013 |
| Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine … PS Dragovich, TJ Prins, R Zhou, SE Webber, JT Marakovits, SA Fuhrman, ... Journal of medicinal chemistry 42 (7), 1213-1224, 1999 | 163 | 1999 |
| Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications Y Zhang, L Zhang, S Abraham, S Apparaju, TC Wu, JM Strong, S Xiao, ... Clinical Pharmacology & Therapeutics 85 (3), 305-311, 2009 | 155 | 2009 |
| Identification of novel substrates for human cytochrome P450 2J2 CA Lee, D Neul, A Clouser-Roche, D Dalvie, MR Wester, Y Jiang, ... Drug metabolism and disposition 38 (2), 347-356, 2010 | 154 | 2010 |
| Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction … CA Lee, MA O’Connor, TK Ritchie, A Galetin, JA Cook, ... Drug metabolism and disposition 43 (4), 490-509, 2015 | 146 | 2015 |
| Abundance of drug transporters in the human kidney cortex as quantified by quantitative targeted proteomics B Prasad, K Johnson, S Billington, C Lee, GW Chung, CDA Brown, ... Drug Metabolism and Disposition 44 (12), 1920-1924, 2016 | 142 | 2016 |
| Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate JH Lillibridge, BH Liang, BM Kerr, S Webber, B Quart, BV Shetty, CA Lee Drug Metabolism and Disposition 26 (7), 609-616, 1998 | 136 | 1998 |
| CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human … CA Lee, SH Kadwell, TA Kost, CJ Serabjitsingh Archives of Biochemistry and Biophysics 319 (1), 157-167, 1995 | 131 | 1995 |
| Transporter expression in liver tissue from subjects with alcoholic or hepatitis C cirrhosis quantified by targeted quantitative proteomics L Wang, C Collins, EJ Kelly, X Chu, AS Ray, L Salphati, G Xiao, C Lee, ... Drug Metabolism and Disposition 44 (11), 1752-1758, 2016 | 115 | 2016 |
| P-glycoprotein related drug interactions: clinical importance and a consideration of disease states CA Lee, JA Cook, EL Reyner, DA Smith Expert opinion on drug metabolism & toxicology 6 (5), 603-619, 2010 | 107 | 2010 |
| Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity CA Lee, JP Jones, J Katayama, R Kaspera, Y Jiang, S Freiwald, E Smith, ... Drug Metabolism and Disposition 40 (5), 943-951, 2012 | 102 | 2012 |
| Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes P Zhao, KL Kunze, CA Lee Drug metabolism and disposition 33 (6), 853-861, 2005 | 100 | 2005 |
| Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 6. Structure− Activity Studies of Orally Bioavailable, 2-Pyridone-Containing … PS Dragovich, TJ Prins, R Zhou, EL Brown, FC Maldonado, SA Fuhrman, ... J. Med. Chem 45, 1607-1623, 2002 | 94 | 2002 |
